Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | S100A9 | P06702 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10064802 | 0.85 | NOTUM (0.41) | CYP2C19RXRARXRBRXRGSLC1A5 | |
| SCHEMBL10936074 | 0.85 | MRGPRX4 (0.48) | SLC1A5MRGPRX4 | |
| SCHEMBL13918953 | 0.81 | KDM4E (0.49) | CYP2C19KDM4ESMN1; SMN2CA1CA2 | |
| SCHEMBL12390582 | 0.79 | PDE2A (0.51) | KDM4ECA1CA2CA9 | |
| SCHEMBL799545 | 0.79 | CYP2C19 (0.56) | CYP2C19RXRARXRBRXRGKDM4E | |
| SCHEMBL12828082 | 0.78 | ALDH1A1 (0.43) | CYP2C19KDM4ESMN1; SMN2CA1CA2 | |
| SCHEMBL12828080 | 0.78 | CA1 (0.42) | CYP2C19SMN1; SMN2CA1CA2CA9 | |
| SCHEMBL13698781 | 0.78 | CA1 (0.42) | CYP2C19SMN1; SMN2CA1CA2CA9 | |
| SCHEMBL17420529 | 0.77 | KMO (0.49) | CYP2C19KMOS100A9MRGPRX4 | |
| SCHEMBL29129639 | 0.77 | SLC1A5 (0.39) | SLC1A5KMOPGK1GRIN2BS100A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-06-21 | — | — | US | disclosed |
| US-11220479-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-11 | — | — | US | disclosed |
| US-11214541-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2022-01-04 | — | — | US | disclosed |
| US-11214563-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-04 | — | — | US | disclosed |
| US-20210323916-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2021-10-21 | — | — | US | disclosed |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-10-19 | — | — | US | disclosed |
| US-11072601-B2 | μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine | SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD. (CN) | 2021-07-27 | — | — | US | disclosed |
| US-9714221-B1 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9302988-B2 | Fluoromethyl-substituted pyrrole carboxamides | Grünenthal GmbH (DE) | 2016-04-05 | — | — | US | disclosed |
| US-8722670-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | GRUENENTHAL GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
| US-20130085138-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| US-7667036-B2 | MAPKAP-K2 (mitogen-activated protein kinase-activated protein kinase 2) inhibitors; inflammatory, autoimmune disease, destructive bone disorder, cancer and/or tumor growth; angiogenesis, diabetes and neurological disorders | TEIJIN PHARMA LIMITED (JP) | 2010-02-23 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | CYP2C19 565/4885RXRA 24/4885RXRB 137/4885 |
| US-11149002-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | CYP2C19 565/4885RXRA 24/4885RXRB 137/4885 |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CYP2C19 4866/4885RXRA 4374/4885RXRB 3801/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CYP2C19 4866/4885RXRA 4374/4885RXRB 3801/4885 |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | CYP2C19 18/4885RXRA 2068/4885RXRB 2018/4885 |
| US-11072601-B2 | μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine | OPRM1, OPRD1, OPRK1 | CYP2C19 1179/4885RXRA 811/4885RXRB 901/4885 |
| US-20130085138-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | CYP2C19 3264/4885RXRA 1503/4885RXRB 1119/4885 |
| US-11214541-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof | CYP19A1, ESR1, GPER1 | CYP2C19 193/4885RXRA 231/4885RXRB 232/4885 |
| US-11220479-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | GBA1, GBA2, GAA | CYP2C19 3713/4885RXRA 2943/4885RXRB 2752/4885 |
| US-11214563-B2 | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators | GRIN2B, GRIN2A, GRIN2C | CYP2C19 1725/4885RXRA 1175/4885RXRB 444/4885 |
| US-20140066426-A1 | FLUOROMETHYL-SUBSTITUTED PYRROLE CARBOXAMIDES | TRPV1, CACNA1B, CACNA1G | CYP2C19 1700/4885RXRA 3601/4885RXRB 2874/4885 |
| US-20210323916-A1 | NOVEL SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | CYP19A1, ESR1, ESR2 | CYP2C19 167/4885RXRA 259/4885RXRB 254/4885 |
| US-11365189-B2 | Heterocyclic inhibitors of tyrosine kinase | ERBB2, ERBB3, EGFR | CYP2C19 1922/4885RXRA 3726/4885RXRB 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.